Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily licensed for the treatment of type 2 diabetes mellitus and, in specific formulations, for weight management
While hair loss isnt a life-threatening condition like diabetes or obesity, the level of innovation in the field is accelerating in a similar way fast, disruptive, and focused on biological reprogramming rather than surface-level fixes
This review describes evidence from previous research on the effects of GLP-1R agonists on obesity
This committee planned the questions on the basis of the findings from the scoping review and identified seven experts [10]three endocrinologists, two cardiologists, and two nephrologistschosen according to their expertise in treating people with diabetes and their experience in formulating local guidelines or leading the implementation of policies within the healthcare system
Type 2 diabetes is the most common cause of CKD, and both diabetes and CKD are associated with increased all-cause mortality and increased rates of infection and cardiovascular events
